Today's Top Stories


Hot Topics


Comment & Analysis »

GlobalData Healthcare

Promising preliminary data from Phase II study encourages Axovant to expand trial

On February 13, 2017, Axovant Sciences, a specialist clinical stage biopharmaceutical company, announced the positive preliminary data from their Phase II dementia study for their 5-HT2A...

Promising preliminary data from Phase II study encourages Axovant to expand trial
GlobalData Healthcare

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data
GlobalData Healthcare

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example
Umesh Ellichipuram

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk
GlobalData Healthcare

Persistence may be Novavax’s greatest asset in its quest to develop an RSV vaccine

Persistence may be Novavax’s greatest asset in its quest to develop an RSV vaccine

Company Releases »

Optimising Development Resources for Efficient Product Development

SYSTAG Systems Technik
Optimising Development Resources for Efficient Product Development

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

SYSTAG Systems Technik
ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

GPC/SEC Analysis of Polymer Solutions Used in Inkjet Printing

Malvern Instruments GPC/SEC Analysis of Polymer Solutions Used in Inkjet Printing

Gold Nanoparticle Applications and Characterization by Nanoparticle Tracking Analysis

Malvern Instruments
Gold Nanoparticle Applications and Characterization by Nanoparticle Tracking Analysis

Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs

Pharmatest Services Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs

Drugdevelopment Insights »

Drugdevelopment Industry Reports »

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Report: Growth Expected in Dyslipidemia market to $29bn by 2025

Report: Growth Expected in Dyslipidemia market to $29bn by 2025

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Report: Partnerships between big pharma and small biotech to dominate Lupus R&D landscape

Report: Partnerships between big pharma and small biotech to dominate Lupus R&D landscape








cachename:HomePagecachekey:rd-1665407042_1729060782_rd-488908060_1460672566_ap1460672566_1729060782_1903286115